Exact Sciences Corporation has announced that it has received all necessary regulatory approvals to proceed with its merger with Abbott Laboratories. This merger, which was initially agreed upon on November 19, 2025, will see Abbott's wholly-owned subsidiary merge with Exact Sciences, allowing Exact to operate as a direct subsidiary of Abbott. The stockholders of Exact Sciences approved the merger during a special meeting held on February 20, 2026. The anticipated closing date for the merger is March 23, 2026, pending the satisfaction or waiver of any remaining conditions outlined in the merger agreement. This merger is expected to enhance Exact's operational capabilities and expand its market reach, potentially leading to significant growth opportunities. The announcement comes with forward-looking statements that highlight the risks and uncertainties associated with the merger, including the possibility of delays or complications in closing. However, the overall sentiment surrounding the merger is positive, as it positions Exact Sciences for future success in the healthcare sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.